The results from the latest EIC (European Innovation Council) Transition Open and Challenges have been recently announced.
Regarding the EIC Transition Open call, there has been a considerable increase in the number of applications received in this second cut-off (287 in contrast to 165 in the first 2022 cut-off). This represents an increase by 74%:
- Applications came from 33 countries,
- From 287 applications, 157 proposals were considered eligible (54.70%), and 27 projects have received funding (17.19% success rate),
- €2.29M average EU grant.
In the case of the EIC Transition Challenges:
- Applications came from 19 countries,
- From 51 applications received, 24 of them were eligible (47%) and 7 projects have received funding (29% success rate).
- €2.49M average EU grant.
What is the EIC Transition programme?
The EIC Transition projects focus on results generated by EIC Pathfinder, FET (Future and Emerging Technologies) or European Research Council (ERC) Proof of Concept projects so as to further develop the technology and build a business case for specific applications.
Grants of up to €2.5 million are given to each project to validate and test technologies in application-relevant environments and develop market readiness (totaling €79.3M). Selected projects receive access to EIC Business Acceleration Services including coaching, mentoring, and partnering events. Projects are also eligible for the fast track scheme to access the EIC Accelerator for supporting the commercialisation and scale up phases.
Research teams, SMEs, spin outs and small consortia (up to 5 partners from different countries) are supported by the EIC Transition to mature and validate their novel technologies. This latest EIC Transition call included targeted funding for clean energy, green digital devices and RNA-based therapies and diagnostics for complex or rare genetic diseases technologies as well as open funding for any area of technology.
The top four countries participants in the EIC Transition Open and the EIC Transition Challenges Calls are Spain, Italy, Germany and France. The table below shows the number of awarded projects per coordinator’s country:
12 out of the 34 approved applications (35%) have been submitted by an RTO as coordinators, that is, either by universities, institutes for research or research centers, while the remaining 22 applications have been submitted by a company as coordinator (65%).
The table below shows the full list of winners:
|Proposal Acronym||Proposal Title||Coordinating Organisation||Country Coordinator||Duration (months)||Recommended Budget|
|BionicVEST-2||EUROPEAN DEVELOPMENT OF A FIRST COMMERCIAL BIONIC VESTIBULAR IMPLANT FOR VESTIBULAR DYSFUNCTION – 2||COCHLEAR BENELUX NV||BE||36||2.498.937,50 €|
|3DPRINTOPTIXMARKET||3D Printed Micro-Optics to the Market||Printoptix GmbH||DE||36||2.496.602,75 €|
|LiveSen-MAP||Real-time nutrient sensing for mapping fertilizer needs||TECHNISCHE UNIVERSITAET MUENCHEN||DE||36||2.499.955,00 €|
|MagSense||Hyperpolarized NMR made simple||NVISION IMAGING TECHNOLOGIES GMBH||DE||24||2.451.913,75 €|
|SPINNODE||SpiNNaker on the Edge||SpiNNcloud Systems GmbH||DE||24||2.500.000,00 €|
|SUPREME||Superconductor-Based Readiness Enhanced Magnetoplasmadynamic Electric Propulsion||NEUTRONSTAR SYSTEMS UG||DE||30||2.499.995,75 €|
|GLASS||Green Laser-Assisted Surface Structuring||Biomimetic||EL||30||2.498.945,00 €|
|CARxALL||Next generation, off-the-shelf CD1a/CCR9-directed CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia||ONECHAIN IMMUNOTHERAPEUTICS||ES||36||2.497.500,00 €|
|HDLN||High-Density Lithium Niobate Photonic Integrated Circuits||VLC PHOTONICS SL||ES||30||1.549.111,25 €|
|QSTACK||Low-power consumption, heavy-metal-free wide-spectrum image sensors for mass-market computer vision applications||QURV TECHNOLOGIES SL||ES||24||2.370.937,50 €|
|RoCCQeT||Real-World Commercial Coherent Quantum Annealing Technology||QILIMANJARO QUANTUM TECH SL||ES||24||2.495.000,00 €|
|SOIL2POWER||SOIL microbial fuel cells TO (2) POWER precise irrigation systems.||ARKYNE TECHNOLOGIES SL||ES||36||2.499.812,50 €|
|TraffikGene-Tx||TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery||UNIVERSIDAD DE SANTIAGO DE COMPOSTELA||ES||36||2.499.000,00 €|
|PeptiCHIP||Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization||Valo Therapeutics Oy||FI||24||2.226.280,00 €|
|SoCool||Solid-State Cooling Technology for Cryogenic Devices||TEKNOLOGIAN TUTKIMUSKESKUS VTT OY||FI||36||1.298.411,00 €|
|GALILEO||The first wide range flow sensor to unlock microfluidic cell analyses for preclinical studies||ELVESYS||FR||24||1.667.500,00 €|
|MAG.NET||Magnetic neural Network for predictive maintenance||Golana Computing||FR||36||2.500.000,00 €|
|MAGNIFY||Multi-lane, high-power Photonic Integrated Circuit-based Erbium-Doped Amplifier||LIGENTEC FRANCE||FR||36||1.584.066,25 €|
|SMARTWAY||Nano meta components for electronic smart wireless systems||THALES||FR||36||2.457.765,00 €|
|SPIN-ION||Hybrid Spintronic Synapses for Neuromorphic Computing||SPIN-ION TECHNOLOGIES||FR||30||2.500.000,00 €|
|Crop4Clima||Resilient and environmentally sustainable engineered crops to address climate change||EVOGENE LTD||IL||32||2.475.562,50 €|
|BIOPURE||Biopharmaceuticals purification by continuous membraneassisted crystallization achieving lower cost and intensified processes||CONSIGLIO NAZIONALE DELLE RICERCHE||IT||36||2.491.245,00 €|
|KEEPER||Key codE based on nanomatErials to Protect sErvices and pRoducts||POLITECNICO DI MILANO||IT||30||2.111.146,25 €|
|PHIRE||Photoacoustic imaging and artificial intelligence-based theranostc approach for cancer||OSPEDALE SAN RAFFAELE SRL||IT||36||2.471.021,25 €|
|PreBiomicsPMT||A metagenomic-based precision-medicine tool for personalized diagnosis, prognosis and treatment of oral diseases||PREBIOMICS SRL||IT||36||2.461.900,00 €|
|ROBIOPSY||UNIVERSITA DEGLI STUDI DI VERONA||UNIVERSITA DEGLI STUDI DI VERONA||IT||36||2.499.141,00 €|
|SILKink||Revolutionary silk-based bioink for 3D printing of ex vivo bone marrow models to advance drug development and personalized medicine||UNIVERSITA DEGLI STUDI DI PAVIA||IT||36||2.494.687,50 €|
|Groove||Germanium quantum processors: more, robust, available||TECHNISCHE UNIVERSITEIT DELFT||NL||24||2.500.000,00 €|
|LUMINODIN||A multipotent fluorescent tracer for imaging cancer lesions during surgery and follow up||ACADEMISCH ZIEKENHUIS LEIDEN||NL||36||2.500.000,00 €|
|BIGALPS||Bio Inspired Geotechnical Applications to Launch PanEuropean Solutions||UNIVERSITATEA TEHNICA CLUJNAPOCA||RO||36||1.756.837,50 €|
|TOPFIBRO||Targeting OGG1 in Idiopathic Pulmonary Fibrosis||OXCIA AB||SE||36||2.500.000,00 €|
|ENABLER||Tech and business validation towards market readiness of high-performance PFSA-free intermetallic Pt-alloy membrane electrode assemblies for PEMFCs: Enabling nextgen hydrogen-based transport||RECATALYST, RAZVOJ, PROIZVODNJA IN PRODAJA KATALIZATORSKIH KOMPOZITOV, D.O.O.||SI||30||2.495.900,00 €|
|GENERA||A revolutionary, highly versatile drug delivery platform based on Metal-Organic Frameworks||Vector Bioscience Cambridge Ltd||UK||36||2.498.082,00 €|
|IBDSENSE||Non-invasive technologies for diagnosis and monitoring of inflammatory bowel diseases||THE UNIVERSITY OF EDINBURGH||UK||36||2.466.590,00 €|